Bristol-Myers Squibb Company v. Amgen Inc. - 1:26-cv-01134

Bristol-Myers Squibb Company v. Amgen Inc. (Case No. 1:26-cv-01134), filed on Sep 8, 2026 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:26-cv-01134
Filing Date
Sep 8, 2026
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Amgen Inc. -
E. R. Squibb & Sons, L.L.C. -
Bristol-Myers Squibb Company -
Ono Pharmaceutical Co., Ltd. -

Patents Involved

This case involves 7 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Sep 8, 2026MOTION for Leave to File Complaint Under Seal - filed by Bristol-Myers Squibb Company, E. R. Squibb & Sons, L.L.C., Ono Pharmaceutical Co., Ltd.. (Attachments: # 1 Proposed Order)(slk) (Entered: 09/09/2026)PACER Document
Sep 8, 2026[SEALED] COMPLAINT with Jury Demand against Amgen Inc. (Filing fee $ 405, receipt number ADEDC-5060234) - filed by Ono Pharmaceutical Co., Ltd., E. R. Squibb & Sons, L.L.C., Bristol-Myers Squibb Company. (Attachments: # 1 Exhibits A-G, # 2 Civil Cover Sheet)(slk) (Entered: 09/09/2026)PACER Document
Sep 8, 2026Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (slk) (Entered: 09/09/2026)PACER Document
Sep 8, 2026Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 8,008,449 B2; US 9,856,320 B2; US 10,072,082 B2; US 12,590,154 B2 ; US 12,624,107 B2; US 12,590,153 B2 ; US 12,479,917 B2. (slk) (Entered: 09/09/2026)PACER Document
Sep 8, 2026Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Bristol-Myers Squibb Company for E. R. Squibb & Sons, L.L.C. filed by Bristol-Myers Squibb Company, E. R. Squibb & Sons, L.L.C. (slk) (Entered: 09/09/2026)PACER Document
Sep 8, 2026Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Ono Pharmaceutical Co., Ltd. (slk) (Entered: 09/09/2026)PACER Document
Sep 9, 2026Summons Issued as to Amgen Inc. on 9/9/2026. (slk) (Entered: 09/09/2026)PACER Document
Sep 9, 2026Remark: Exit Electronic Copies to Duty Judge (GBW). (slk)PACER Document
Sep 9, 2026NOTICE of Appearance by James L. Higgins on behalf of Amgen Inc. (Higgins, James) (Entered: 09/09/2026)PACER Document
Sep 10, 2026DEFICIENCY NOTICE issued by the Court to Defendant: Pursuant to Fed. R. Civ. P. 7.1 (b)(1), A party must: (1) file the disclosure statement with its first appearance, pleading, petition, motion, response, or other request addressed to the court. Counsel is requested to supplement the docket with an appropriate Rule 7.1 Disclosure Statement. (nms)PACER Document
Sep 10, 2026ORDER re 1 MOTION for Leave to File Complaint Under Seal filed by Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, E. R. Squibb & Sons, L.L.C. Signed by Judge Gregory B. Williams on 9/9/2026. (lnb) (Entered: 09/10/2026)PACER Document
Sep 10, 2026Remark: Case submitted for routine judicial assignment. (slk)PACER Document